BREXIT shook the whole world when United Kingdom voted in favour of leaving the EU. After the vote, the country has been wrought in uncertainty related to political, regulatory and economic scenario. Brexit has led to deliberations regarding modified supply chain requirements, uncertain regulatory scenario, revised intellectual property laws, and depreciating currency. The research and development wing of the pharmaceutical industry, however, hopes to get a boost in terms of clinical trials as the UK will now have to look for economical collaborators, considering the lack of funding from the Union. The position of UK at this point teeters on the edge, and it is directly related to the direction Brexit takes the country. The whitepaper on the same topic discusses what transpired, and what is happening in the UK, and how it can change the course of Pharma industry of the country.
To download, click here.